| http://dbpedia.org/ontology/abstract
|
CRLX101 is a experimental approach to canc … CRLX101 is a experimental approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine. The agent represents a nanoparticle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) and an anti-cancer compound (camptothecin). It was developed by Mark E. Davis, professor of Chemical Engineering at the California Institute of Technology, and associates at Insert Therapeutics, Inc., now Calando Pharmaceuticals, Inc., hence the original name "IT-101". Its novel delivery mode allows the agent, and thus the toxic anti-cancer component, to be preferentially accumulated in cancer tissue. In turn, toxic side effect are expected to be reduced. The technology was licensed by Calando and Caltech to Cerulean Pharma, in 2009.o and Caltech to Cerulean Pharma, in 2009.
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.ceruleanrx.com/ +
, http://www.calandopharma.com/ +
, http://www.thirteen.org/curious/episodes/qa-mark-davis/ +
, http://www.che.caltech.edu/groups/med/index.html +
|
| http://dbpedia.org/ontology/wikiPageID
|
15028090
|
| http://dbpedia.org/ontology/wikiPageLength
|
3555
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1103948070
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Conjugation_%28biochemistry%29 +
, http://dbpedia.org/resource/Mark_E._Davis +
, http://dbpedia.org/resource/Alkaloid +
, http://dbpedia.org/resource/Polymer +
, http://dbpedia.org/resource/Translational_Genomics_Research_Institute +
, http://dbpedia.org/resource/Cancer +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/City_of_Hope_National_Medical_Center +
, http://dbpedia.org/resource/Camptotheca_acuminata +
, http://dbpedia.org/resource/Molecule +
, http://dbpedia.org/resource/California_Institute_of_Technology +
, http://dbpedia.org/resource/Polyethylene_glycol +
, http://dbpedia.org/resource/Nanomedicine +
, http://dbpedia.org/resource/Camptothecin +
, http://dbpedia.org/resource/Enhanced_permeability_and_retention_effect +
, http://dbpedia.org/resource/Chemotherapy +
, http://dbpedia.org/resource/Glycine +
, http://dbpedia.org/resource/Topoisomerase +
, http://dbpedia.org/resource/Insert_Therapeutics +
, http://dbpedia.org/resource/Cyclodextrin +
, http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Unreferenced_section +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Approach +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/CRLX101?oldid=1103948070&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/CRLX101 +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q5013907 +
, https://global.dbpedia.org/id/4eSXU +
, http://rdf.freebase.com/ns/m.03h52vk +
, http://yago-knowledge.org/resource/CRLX101 +
, http://dbpedia.org/resource/CRLX101 +
|
| rdf:type |
http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/class/yago/Medicine103740161 +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/class/yago/CytotoxicDrug103157987 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/ontology/ProgrammingLanguage +
, http://dbpedia.org/class/yago/Antineoplastic102722458 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Drug103247620 +
, http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/WikicatExperimentalCancerDrugs +
|
| rdfs:comment |
CRLX101 is a experimental approach to canc … CRLX101 is a experimental approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine. The agent represents a nanoparticle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) and an anti-cancer compound (camptothecin). It was developed by Mark E. Davis, professor of Chemical Engineering at the California Institute of Technology, and associates at Insert Therapeutics, Inc., now Calando Pharmaceuticals, Inc., hence the original name "IT-101". Its novel delivery mode allows the agent, and thus the toxic anti-cancer component, to be preferentially accumulated in cancer tissue. In turn, toxic side effect are expected to be reduced. The technology was licensed by Calando and Caltech to Cerulean Pharma,by Calando and Caltech to Cerulean Pharma,
|
| rdfs:label |
CRLX101
|
